 |
|
Identification of signature gene set as highly accurate determination of metabolic dysfunction-associated steatotic liver disease progression
Sumin Oh, Yang-Hyun Baek, Sungju Jung, Sumin Yoon, Byeonggeun Kang, Su-hyang Han, Gaeul Park, Je Yeong Ko, Sang-Young Han, Jin-Sook Jeong, Jin-Han Cho, Young-Hoon Roh, Sung-Wook Lee, Gi-Bok Choi, Yong Sun Lee, Won Kim, Rho Hyun Seong, Jong Hoon Park, Yeon-Su Lee, Kyung Hyun Yoo
Clin Mol Hepatol. 2024;30(2):247-262. Published online 2024 Jan 26 DOI: https://doi.org/10.3350/cmh.2023.0449
|
|
Citations to this article as recorded by
 Association between advanced fibrosis and epigenetic age acceleration among individuals with MASLD
Haili Wang, Zhenqiu Liu, Hong Fan, Chengnan Guo, Xin Zhang, Yi Li, Suzhen Zhao, Luojia Dai, Ming Zhao, Tiejun Zhang
Journal of Gastroenterology.2025; 60(3): 306. CrossRef Correspondence to editorial on “DNA methylome analysis reveals epigenetic alteration of complement genes in advanced metabolic dysfunction-associated steatotic liver disease”
Amal Magdy, Hee-Jin Kim, Won Kim, Mirang Kim
Clinical and Molecular Hepatology.2025; 31(1): e70. CrossRef PNPLA3 is one of the bridges between TM6SF2 E167K variant and MASLD: Correspondence to editorial on “TM6SF2 E167K variant decreases PNPLA3-mediated PUFA transfer to promote hepatic steatosis and injury in MASLD”
Baokai Sun, Likun Zhuang
Clinical and Molecular Hepatology.2025; 31(1): e67. CrossRef The gene expression signature of metabolic dysfunction- associated steatotic liver disease from a multiomics perspective
Carlos Jose Pirola, Silvia Sookoian
Clinical and Molecular Hepatology.2024; 30(2): 174. CrossRef Correspondence on Editorial regarding “Identification of signature gene set as highly accurate determination of MASLD progression”
Sungju Jung, Sumin Yoon, Jong Hoon Park, Yeon-Su Lee, Kyung Hyun Yoo
Clinical and Molecular Hepatology.2024; 30(2): 287. CrossRef Correspondence to editorial on “Multiomics profiling of buffy coat and plasma unveils etiology-specific signatures in hepatocellular carcinoma”
Su Bin Lim, Hyo Jung Cho
Clinical and Molecular Hepatology.2024; 30(4): 1009. CrossRef Chitinase 1: a novel therapeutic target in metabolic dysfunction-associated steatohepatitis
Jung Hoon Cha, Na Ri Park, Sung Woo Cho, Heechul Nam, Hyun Yang, Eun Sun Jung, Jeong Won Jang, Jong Young Choi, Seung Kew Yoon, Pil Soo Sung, Si Hyun Bae
Frontiers in Immunology.2024;[Epub] CrossRef Metabolic dysfunction-associated steatotic liver disease: a key factor in hepatocellular carcinoma therapy response
Camilo Julio Llamoza-Torres, María Fuentes-Pardo, Bruno Ramos-Molina
Metabolism and Target Organ Damage.2024;[Epub] CrossRef Biological and clinical role of TREM2 in liver diseases
Ke Ma, Shouliang Guo, Jin Li, Tao Wei, Tingbo Liang
Hepatology Communications.2024;[Epub] CrossRef
|